Qiagen, headquartered in Venlo, Netherlands, is a leading global provider of sample and assay technologies. The company was founded in 1984 by German entrepreneur Detlev Riesner and Dutch physician Metin Colpan, initially as a spin-off from the University of Düsseldorf. Qiagen's primary focus is on simplifying and accelerating the laboratory workflows for life sciences, diagnostics, and applied testing.

Qiagen offers a wide range of products and services, including sample and assay technologies, bioinformatics solutions, and automated instruments for processing samples. Its products find application in areas such as infectious diseases, cancer research, genetic testing, drug discovery, and forensics. Qiagen's sample technologies enable the isolation and purification of DNA, RNA, and proteins from various biological samples with high precision and efficiency.

Meanwhile, its assay technologies facilitate the detection and analysis of specific targeted molecules. Qiagen operates globally, with presence in over 35 countries, and serves customers in more than 160 countries. The company has numerous subsidiaries, joint ventures, and partnerships that contribute to its global strategy.

Notable subsidiaries include Qiagen Sciences Inc. Additionally, Qiagen has formed strategic partnerships with major players in the industry, such as Thermo Fisher Scientific and Illumina. In terms of market position, Qiagen is considered one of the leading companies in the life sciences and molecular diagnostics markets.

With annual revenues exceeding $1 billion, Qiagen has a strong global sales presence. It competes with other major players such as Roche, Agilent Technologies, and Illumina. Over the years, Qiagen has achieved several notable milestones.

In 1996, the company introduced the QIAcube, an automated sample preparation instrument, revolutionizing laboratory workflows. In 2013, Qiagen launched the GeneReader NGS System, a next-generation sequencing platform for clinical research. Furthermore, Qiagen has continually expanded its product portfolio through acquisitions and partnerships, enhancing its capabilities and market reach.

As of the latest available information, Qiagen announced in 2019 its plans to form a strategic partnership with Illumina for the development and commercialization of next-generation sequencing-based in vitro diagnostic kits. This collaboration aims to facilitate the integration of molecular testing in clinical research, diagnosis, and treatment decision-making. In conclusion, Qiagen is a globally recognized company in the field of sample and assay technologies.

With its innovative products, extensive global presence, and strategic partnerships, Qiagen continues to play a vital role in advancing research and diagnostics worldwide